Perfil de progesterona em novilhas com diferente atividade luteal e tratadas com implantes vaginais / Serum progesterone in heifers with different luteal activity treated with vaginal devices

O dispositivo de liberação de progesterona (DLP) é muito importante em protocolos de Inseminação Artificial em Tempo Fixo (IATF). Representa cerca de 43% dos custos e é objeto de estudos sobre a eficiência da sua reutilização. No entanto, perfis de liberação de progesterona (P4) em animais com diferentes concentrações endógenas desse esteroide não são claramente descritos. Este estudo teve como objetivo avaliar a concentração sérica de P4 em fêmeas com diferentes situações de atividade luteal, tratadas com DLP novo (1g de P4) por 8 dias. Trinta novilhas mestiças cíclicas foram divididas em três grupos: em G1 e G2, o DLP foi inserido (D0) sete dias após a ovulação induzida. Adicionalmente, 0,15mg de D-cloprostenol foi administrado três dias depois para promover a luteólise em G2. Para G3, o corpo lúteo foi lisado antes da inserção do DLP para que a P4 exógena fosse a única fonte desse hormônio. O sangue foi coletado no D0, D3, D5 e D8, e a P4 avaliada por RIA. Médias de P4 foram comparadas entre os grupos em cada dia e dentro do grupo, entre os dias, utilizando o teste Tukey. Antes da inserção do implante (D0), os níveis de P4 foram, nos grupos, semelhantes em G1 e G2, e superiores a G3 (5,3±3,1a e 5,3±1,4avs 0,6±0.3bng/mL, respectivamente-P<0,05). No D3, ocorreu o mesmo perfil (5,7±2,6a e 5,4±2,0a e 3,6±0.8bng/mL, respectivamente para G1 e G2 vs G3, P<0,05). Trinta e seis horas (D5) após a PGF, a P4 no G2 caiu para níveis semelhantes aos do grupo G3 e ambos diferiram (P<0,05) de G1 (3,3±1,6b vs 2,4±0,9b e 2,1±0.7bng/mL). Essa diferença se manteve (P<0,05) em D8 (3,1±1,3a, 1,8±0,8b e 1,6±0.6b ng/mL). O aumento da P4 após a inserção (D3 - D0) foi maior (P<0,05) em G3 que em G1 e G2 (2,8±0,9a vs 0,4±1,8b e 0,2±1.4bng/mL). Os animais com maior P4 endógena levam a menor liberação de P4 exógena a partir do DLP. Portanto, os níveis remanescentes de P4 no DLP após o uso dependem da concentração endógena de P4 do animal e possíveis alterações durante a permanência.(AU)

The progesterone (P4) device is a very important step in the ovulation control in Timed Artificial Insemination (TAI) protocols. It represents about 43% of the hormone costs, thus it has been the subject of several studies on efficiency of the reused device as an alternative to reduce TAI costs. However, to our knowledge, profiles for P4 release in animals with different endogenous concentrations of P4 are not clearly described. This study aimed to evaluate serum concentration of P4 in females with different ovarian conditions - related to luteal activity - and treated with a new intravaginal device (1g of P4) for 8 days. Thirty normally cyclic crossbred heifers were divided into three groups: for G1 and G2, P4 device was inserted (D0) seven days after ovulation (7 day old CL). Additional PGF (0.15 mg of D-cloprostenol) was given three days later to promote luteolysis in the G2 group. For G3, CL was killed before P4 insertion and the exogenous progesterone was the only source of this hormone. Blood samples were collected on D0, D3, D5 and D8 and P4 concentration was measured by radioimmunoassay (RIA). Means for P4 concentration were compared among groups in each day and within the group among days using the Tukey test. Before P4 device insertion (D0), P4 levels were higher (P<0.05) in G1 and G2 when compared to G3 (5.3±3.1 and 5.3±1.4 vs. 0.6±0.3ng/mL, respectively). Three days later (D3), the same pattern was observed (5.7±2.6 and 5.4±2.0 and 3.6±0.8ng/mL, respectively for G1 and G2 vs. G3, P<0.05). Thirty-six hours (D5) after PGF injection (G2), P4 in G2 dropped to levels similar to the G3 group and both differed (P<0.05) from G1 (3.3±1.6 vs. 2.4±0.9 and 2.1±0.7ng/mL, G1 vs. G2 and G3, respectively). There were no differences (P>0.05) among groups on D8 (3.1±1.3, 1.8±0.8 and 1.6±0.6ng/mL, respectively, for G1, G2 and G3). Progesterone increase after P4 insertion (D3 - D0) was higher (P<0.05) in G3 compared to G1 and G2 (2.8±0.9 vs. 0.4±1.8 and 0.2±1.4ng/mL, respectively). The interpretation was that animals with higher endogenous P4 promote less release of the exogenous P4 from the device. Therefore, the remaining P4 levels from used progesterone devices depend on the physiological condition of the animal at the time of insertion and possible changes during the treatment.(AU)

Formulation and pharmacokinetic study of ranitidine hydrochloride suppositories

The present work is an extension of previous effect of certain excipients on the bioavailability of ranitidine hydrochloride. It was concluded that sodium sulphate ranitidine hydrochloride mixture in ratio 1:1 in both physical and coground mixtures are the excipient of choice for overcoming the hygroscopic nature of ranitidine. Also, statistical analysis of the pharmacokinetic data revealed that coground mixture gave more relative bioavailability than the physical mixture. Influence of the hydrophobicity of different fatty suppository bases on the dissolution profile of ranitidine hydrochloride coground mixture was studied. Witepsol W[25], W[3], and W[35] either single base or blends in [1:1] w/w ratio were used as hydrophobic suppository bases. Weight variation, content uniformity, hardness and melting range tests were conducted on the formulations. In vitro release was carried out according to USP basket method. Shelf storage of bases showing the highest drug release namely Witepsol W[25], W[25]+W[35], W[25]+W[31], showed no significant change in the drug release. Witepsol W[25] was subjected to in-vivo availability study as representative of the most promising formula according to the in vitro release data. The in-vivo availability and pharmacokinetic studies of the selected formula as well as on the oral administration of commercial product and coground mixture to act as reference product revealed that for practical use the dose of suppositories should be 60% of the oral dose of coground mixture according to AUC[0-6] values

Formulación y control de supositorios rectales pediátricos de metronidazol / Formulation and control of suppositories of metronidazole

El estudio de los aspectos tecnológicos para la Formulación del Metronidazol bajo la Forma Farmacéutica de Supositorios y su posterior control, plantea una primera alternativa para reemplazar la terapia parenteral de este principio activo, la cual resulta extremadamente costosa. La minuciosa selección del excipiente mezclando diferentes concentraciones de Carbowax con bases para supositorios hidrosolubles comerciales constituyó la búsqueda, con el fin de asegurar eficacia y estabilidad, obteniéndose una combinación de los mismos que al incorporar el Metronidazol conllevó lograr los Supositorios finales, los cuales al ser evaluados en cada uno de los parámetros establecidos para esta forma farmacéutica infieren que el producto es homogéneo tanto en sus carácteres físicos como en el contenido de Metronidazol